Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cancer Research UK announces £45m investment in clinical trials
The funding has been allotted to spend over five years across eight CTUs in Cardiff, Birmingham, Glasgow, Southampton, Leeds and London. The CTUs are engaged in the designing, delivery
The funding has been allotted to spend over five years across eight CTUs in Cardiff, Birmingham, Glasgow, Southampton, Leeds and London. The CTUs are engaged in the designing, delivery
Headquartered in New York, Flatiron Health is a provider of oncology-specific electronic health record (EHR) software. The company, which was founded in 2012, is also engaged into curation
The FDA approval secured by the Johnson & Johnson (J&J) subsidiary comes after last week’s results of the phase 3 SPARTAN trial in patients with NM-CRPC in which
The approval is for Glatopa 40mg/mL as a fully-substitutable, AP-rated generic version of Teva Pharmaceutical Industries’ three times-a-week Copaxone 40mg/mL therapy (glatiramer acetate injection). Glatopa was approved by
Discovered by Kyowa Hakko Kirin, Tivozanib is an oral, once-daily and vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). In the European Union, Norway and Iceland, tivozanib
The approval from the US Food and Drug Administration (FDA) is for CF patients having two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator
The collaboration and license agreement will see both companies evaluate novel bispecific immuno-oncology agents that combine Pieris’ anticalin technology with select Seattle Genetics cancer-targeted antibodies. The companies will
The placebo-controlled trial was held in over 1,200 men with nonmetastatic, castration-resistant prostate cancer, who were at high risk for the development of metastasis in spite of being
Bictegravir is one of the three drugs used in Biktarvy, which secured approval from the US Food and Drug Administration (FDA) for the treatment of human immunodeficiency virus type
The companies have signed a global co-development and commercialization agreement that could generate up to $1bn for Theravance. Theravance's TD-1473 is an internally-discovered Janus kinase (JAK) inhibitor that has demonstrated